Carcinoma News and Research RSS Feed - Carcinoma News and Research

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
Immature blood vessels linked to poor sunitinib response

Immature blood vessels linked to poor sunitinib response

Patients with clear-cell renal cell carcinoma with relatively mature blood vessels respond better to sunitinib and have fewer metastatic sites than those with immature vessels, a study has found. [More]
ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, led by David Garcia-Mollev- have identified 5 genes differentially expressed in normal accompanying cells in colorectal tumors. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]
Cancer-fighting cocktail shows promising results for advanced cervical cancer

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds. [More]
Researchers examine whether new drug offers added benefit for patients with chronic HCV

Researchers examine whether new drug offers added benefit for patients with chronic HCV

The drug simeprevir has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection. [More]
New immuno-oncology drug helps body's own immune system to fend off cancer

New immuno-oncology drug helps body's own immune system to fend off cancer

According to an August 25 Reuters report, the U.S. Food and Drug Administration is likely to approve Merck & Co.'s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline. [More]
Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

A genetic mutation caused by ultraviolet light is likely the driving force behind millions of human skin cancers, according to researchers at the Stanford University School of Medicine. [More]
Study finds no association between bra wearing and increased breast cancer risk

Study finds no association between bra wearing and increased breast cancer risk

A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. [More]
Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer. [More]
Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221. [More]
Scientists identify genetic mutations in endometrioid endometrial carcinoma

Scientists identify genetic mutations in endometrioid endometrial carcinoma

Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same. [More]
VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy. [More]
High PD-L1 expression linked to reduced survival in NSCLC

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report. [More]
Trovagene announces results from clinical studies on urine-based diagnostic test for detection of HPV

Trovagene announces results from clinical studies on urine-based diagnostic test for detection of HPV

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus. [More]
Scientists identify biomarker strongly associated with aggressive breast cancer

Scientists identify biomarker strongly associated with aggressive breast cancer

Two Northwestern University scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer. [More]
Research findings call for clinical testing of relevant drugs to prevent NASH

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation. [More]
Lymphocyte count predicts papillary RCC patient survival

Lymphocyte count predicts papillary RCC patient survival

Lymphopenia is a significant predictor of outcome in patients undergoing surgery for papillary renal cell carcinoma, US researchers report. [More]
Loyola dermatopathologist recognized by ASCP for achievements in the medical laboratory field

Loyola dermatopathologist recognized by ASCP for achievements in the medical laboratory field

Dermatopathologist, Jodi J. Speiser MD, Assistant Professor of Pathology, Loyola University Stritch School of Medicine, has been named one of the American Society for Clinical Pathology's "40 Under 40" for her achievements in the medical laboratory field. [More]
First-line sunitinib superior to everolimus for metastatic RCC

First-line sunitinib superior to everolimus for metastatic RCC

Results for the RECORD-3 trial support the current strategy of first-line sunitinib followed by second-line everolimus for the treatment of patients with metastatic renal cell carcinoma. [More]